2nd Edition

Breast Cancer Prognosis, Treatment, and Prevention

Edited By Jorge R. Pasqualini Copyright 2008
    608 Pages
    by CRC Press

    608 Pages
    by CRC Press

    Now in its second edition, this bestselling title has been extensively revised and expanded to include new topics on:











    • obesity and breast cancer


    • induction of anti-hormone and anti-growth factor resistance in breast cancer


    • clinical implications of testosterone and breast cancer


    • insulin-like growth factors


    • discussions on the biological, genetic, and molecular pathways linked to the development and progression of breast cancer


    • analyses on the latest therapeutic strategies, prognostic and predictive factors, and prevention strategies








    Examining new developments, Breast Cancer: Prognosis, Treatment, and Prevention, Second Edition also covers:











    • the mechanism involved in carcinogenesis


    • the relationship among a fetus, pregnancy, and breast cancer


    • recent developments in endocrine treatment


    • the relationship among hormone replacement therapy, cytotoxic therapy, and other non-hormonal approaches for the treatment of metastases


    • management of locally advanced breast cancer, and the importance of BRCA-1 and BRCA-2 in hereditary breast cancer








    With new topics and updated chapters, this new edition keeps both oncologists and radiologists abreast of the current trends and advancements in the prognosis, treatment, and prevention of breast cancer.

    Breast Architecture and the Pathogenesis of Cancer. The Enzymatic Systems in the Formation and Transformation of Estrogens in Normal and Cancerous Human Breast. Control and Potential Clinical Applications. Pregnancy and Breast Cancer. The cellular origins of breast cancer subtypes. The Importance of Estrogen Receptors in Breast Cancer. Progesterone Receptor Isoforms and Human Breast Cancer. Compensatory signaling promoted by anti-hormones and anti-growth factor therapies in breast cancer: a starting point for the development of resistance to targeted treatments. Apoptosis, cell death, and breast cancer. Aromatase Inhibitors and Their Application to the Treatment of Breast Cancer. Aromatase Inhibition In Breast Cancer: Update of Clinical Applications. Testosterone and another androgens in breast cancer: Clinical Implications. Combination of breast cancer prevention with tissue-targeted hormone replacement therapy. Practical progress in the chemoprevention of breast cancer with selective estrogen receptor modulators (SERMs). Oncostatic effect of analogs of LHRH on breast cancer. Vitamin D and Breast Cancer. Insulin-like Growth Factor Signaling in Normal Mammary Gland Development and Breast Cancer Progression. Insulin-like Growth Factor-I and Breast Cancer: Epidemiological and Clinical Data. Proliferation of breast cells by steroid hormones and their metabolites. Lignans and Breast Cancer. Breast Cancer Risk, Soyfood Intake and Isoflavone Exposure: A Review of the In Vitro, Animal, Epidemiologic, and Clinical Literature. Body Size and Breast Cancer. Antiangiogenic therapy of breast cancer: Rationale and clinical results. Cytotoxic Therapy and Other Non-Hormonal Approaches for the Treatment of Metastatic Breast Cancer. Adjuvant and Neoadjuvant Systemic Chemotherapy for Operable and Locally Advanced Breast Cancer. BRCA1, BRCA2, and Hereditary Breast Cancer.

    Biography

    JORGE R. PASQUALINI is Director of the Hormones and Cancer Research Unit at the Institut de Puériculture of Paris. Professor Pasqualini received his Ph.D. in biology from the University of Buenos Aires, Argentina, and a D.Sc. degree in Endocrinology from the University of Paris, France. He has published more than 600 original papers and is the founder and Editor-in-Chief of The Journal of Steroid Biochemistry and Molecular Biology, which is considered to be one of the leading international scientific journals in the field. Professor Pasqualini has worked in varying areas of endocrinology and reproduction, and in recent years found new aspects of the production, control, and biological effect of estrogens, anti-estrogens, and progestins in human breast and endometrial cancers, with potential clinical applications in pre- and postmenopausal patients.